Drug Safety Prediction AI Startup Quris Earns Additional Seed Funding Led by SoftBank Vision Fund 2
Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, has announced it has secured an additional $9 million in seed funding, bringing its total seed round funding to $37 million. Led by SoftBank Vision Fund 2, alongside existing private and institutional investors such as GlenRock Capital, iAngels, Welltech Ventures and Richter Group, the additional funding will help Quris advance its Bio-AI platform, grow its team, strengthen industry collaborations and speed its novel drug research.
“We believe the early forecasting capability that Quris is developing brings real potential impact to the global pharmaceutical industry,” said Yossi Cohen, Director of Israel Operations for SoftBank Investment Advisers. ”Harnessing the novel application of AI, Dr. Bentwich and his team could save the enormous costs of drugs failing in clinical trials, and in doing so create a business in Israel of significant economic value.”
Quris is the first Bio-AI clinical-prediction platform that simulates clinical trials by leveraging a patented patient-on-chip system through the use of stem-cell derived tissue and AI to simulate a real human body’s reaction to drugs without relying on time-intense, inaccurate animal-testing. Better predicting which drug candidates will safely work in humans, Quris reduces drug development cost and duration.
“SoftBank’s ecosystem comprises an impressive cluster of companies leading the field of artificial intelligence for pharma. As an investment partner, it gives them a unique perspective on this young and promising field that has already begun to produce significant unicorns,” added Dr. Isaac Bentwich, founder and CEO of Quris.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more